{
    "clinical_study": {
        "@rank": "156426", 
        "arm_group": {
            "arm_group_label": "Debio 1143, Paclitaxel, Carboplatin", 
            "arm_group_type": "Experimental", 
            "description": "Eligible participants received oral Debio1143 once daily for 5 days every 21 days in combination with Paclitaxel (175mg/m2 on Day 1 every 21-day) and Carboplatin (AUC of 6 mg.min/mL on Day 1 every 21-day)."
        }, 
        "brief_summary": {
            "textblock": "To determine the MTD of Debio 1143 when administered in combination with full doses of\n      paclitaxel and carboplatin in patients with squamous NSCLC, Pt-refractory ovarian cancer,\n      and basal-like/claudin low TNBC."
        }, 
        "brief_title": "Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female \u226518 years of age.\n\n          2. Willing and able to sign written informed consent;\n\n          3. Histologically confirmed diagnosis of:\n\n               -  Squamous NSCLC candidate for paclitaxel and carboplatin chemotherapy,\n\n               -  Platinum-refractory primary or secondary ovarian cancer, defined as clinical\n                  recurrences that takes place within 6 months of completion of a Pt-containing\n                  regimen (http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial)\n\n               -  TNBC basal-like and claudin low subtypes candidate for paclitaxel and\n                  carboplatin chemotherapy.\n\n          4. Availability of pre-treatment tumour sample (biopsy or tumour block);\n\n          5. Advanced or metastatic disease;\n\n          6. Measurable disease by the RECIST criteria;\n\n          7. QTcF interval \u2264 450 milliseconds;\n\n          8. Negative Hepatitis B and Hepatitis C testing:\n\n               -  Hepatitis B screening tests: HepB sAg, Anti-HepB sAg, Anti-HepB core IgG,\n\n               -  Hepatitis C screening test: HCV-RNA.\n\n          9. Women of child-bearing potential:\n\n               -  Negative pregnancy test at screening;\n\n               -  Agreement to use appropriate contraception methods from study entry to 6 months\n                  after the last day of treatment.\n\n         10. Male patients agree to use contraception methods from study entry to 6 months after\n             the last day of treatment;\n\n         11. ECOG performance score 0 or 1;\n\n         12. Subjects must have adequate haematological, renal, and hepatic function: calculated\n             creatinine clearance \u2265 50 mL/min as determined by the modified method of Cockcroft\n             and Gault or by the EDTA method; ANC \u2265 1500/\u03bcL, platelets \u2265 100000/\u03bcL, Hb \u2265 9 gm/dL\n             (5 mmol/L), AST and ALT less than 4 times the ULN; total bilirubin \u2264 2.0 mg/dL.\n\n         13. LVEF within the institutional normal ranges as measured by ECHO or MUGA scan;\n\n         14. Able to swallow whole capsules with water at study inclusion;\n\n         15. Life expectancy of at least 3 months in the best judgment of the Investigator;\n\n         16. No prior treatment with IAP inhibitors;\n\n         17. No use or requirement for use of aspirin or aspirin containing products with > 81 mg\n             of aspirin per day;\n\n         18. No history of gastrointestinal bleeding within 1 year;\n\n         19. No active rheumatoid arthritis, active inflammatory bowel disease, chronic infections\n             or any other disease or condition associated with chronic inflammation.\n\n        Exclusion Criteria:\n\n          1. Suitable for any curative treatment;\n\n          2. Unresolved \u2265 Grade 2 toxicity from previous treatment;\n\n          3. Symptomatic brain metastases;\n\n          4. Concomitant use of strong inducers or inhibitors of CYPs 2C8 and 3A4;\n\n          5. Gastro-intestinal disorders that could affect drug absorption (including, but not\n             limited to, major abdominal surgery, significant bowel obstruction, ulcerative\n             colitis, Crohn's disease);\n\n          6. Concurrent treatment with any other systemic anti-cancer therapy that is not\n             specified as part of the protocol regimen;\n\n          7. Concomitant treatment with any drug on the prohibited medication list (provided\n             separately);\n\n          8. Subjects with known history of uncontrolled or symptomatic angina, arrhythmias or\n             congestive heart failure;\n\n          9. History of another malignancy within the last 5 years, with the exception of\n             completely resected basal or squamous cell skin cancer, or successfully treated\n             in-situ carcinoma. History of non-invasive lesion or in-situ carcinoma, including in\n             the head and neck region that was successfully treated with surgery, photodynamics or\n             laser, will be permitted;\n\n         10. Peripheral neuropathy \u2265 grade 2;\n\n         11. If female, pregnant or lactating;\n\n         12. History of allergic reactions to appropriate antiemetics (e.g. 5-HT3 antagonists) to\n             be administered with chemotherapy;\n\n         13. The Investigator considers the subject unfit for the study as a result of the medical\n             interview, physical examinations, or screening investigations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930292", 
            "org_study_id": "Debio 1143-103"
        }, 
        "intervention": [
            {
                "arm_group_label": "Debio 1143, Paclitaxel, Carboplatin", 
                "intervention_name": "Debio 1143", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Debio 1143, Paclitaxel, Carboplatin", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Debio 1143, Paclitaxel, Carboplatin", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 9, 2013", 
        "link": {
            "description": "Site Debiopharm SA", 
            "url": "http://www.debiopharm.com"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Nicolas Isambert, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21079"
                    }, 
                    "name": "Centre Georges Fran\u00e7ois Leclerc"
                }, 
                "investigator": {
                    "last_name": "Nicolas Isambert, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Isabelle Ray-Coquard, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69008"
                    }, 
                    "name": "Centre L\u00e9on B\u00e9rard"
                }, 
                "investigator": {
                    "last_name": "Isabelle Ray-Coquard, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christophe Le Tourneau, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75248"
                    }, 
                    "name": "Institut Curie"
                }, 
                "investigator": {
                    "last_name": "Christophe Le Tourneau, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jean-Pierre Delord, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31052"
                    }, 
                    "name": "Institut Claudius Regaud"
                }, 
                "investigator": {
                    "last_name": "Jean-Pierre Delord, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 Combined With Carboplatin and Paclitaxel in Patients With Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-refractory Ovarian Cancer, and Basal-like/Claudin Low Triple Negative Breast Cancer", 
        "other_outcome": {
            "description": "Assessment of preliminary antitumor activity of the combination of Debio 1143 with Carboplatin and Paclitaxel ; Overall response rate = complete response + partial response", 
            "measure": "Overall response rate", 
            "safety_issue": "No", 
            "time_frame": "Every 42 days from the date of baseline visit"
        }, 
        "overall_contact": {
            "last_name": "Claudio Zanna, MD", 
            "phone": "+41213210111"
        }, 
        "overall_contact_backup": {
            "last_name": "Christian Aeschlimann, MS", 
            "phone": "+41213210111"
        }, 
        "overall_official": {
            "affiliation": "Institut Claudius Regaud, Toulouse, France", 
            "last_name": "Jean-Pierre Delord, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or the recommended dose for expansion (RDE). Safety(incidence and nature of DLTs), pharmacokinetic and pharmacodynamic data will guide dose escalation decisioins.", 
            "measure": "Incidence rate of dose limiting toxicities (DLTs) of Debio1143 in combination with Carboplatin and Paclitaxel", 
            "safety_issue": "Yes", 
            "time_frame": "Approximately 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930292"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions and reductions", 
                "measure": "Safety and tolerability of Debio 1143 combination at the recommended dose (RDE)for expansion", 
                "safety_issue": "Yes", 
                "time_frame": "Every 21 days from baseline visit to 28 days after study drug discontinuation"
            }, 
            {
                "measure": "Plasma concentration of Inhibition Apoptosis Protein (IAP)", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1: every day for 5 days, then at day 8 and day 15"
            }, 
            {
                "description": "Plasma concentration versus time profiles. Plasma PK parameters will be used to characterize the PK profiles of the combination of Debio 1143 with Carboplatin and Paclitaxel", 
                "measure": "Time vs. concentration profile of Debio 1143, Carboplatin and Paclitaxel", 
                "safety_issue": "Yes", 
                "time_frame": "Every 21 days for up to 6 cycles"
            }
        ], 
        "source": "Debiopharm International SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Debiopharm International SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}